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Background: FOLFOX-based adjuvant chemotherapy is a benefit for high-risk stage II and stage III colon cancer
after curative resection. But, the prognostic factor or predictive marker for the efficacy of FOLFOX remains unclear.
This study was aimed to identify the prognostic value and cumulative impact of adjuvant FOLFOX on the stage II
and III colon cancer patients.
Methods: A total of 196 stage II and III colon cancer patients were retrospectively enrolled in prospectively
collected data. They underwent curative resection followed by FOLFOX4 adjuvant chemotherapy. The oncological
outcomes included the 5-year disease-free survival (DFS) rate and 5-year overall survival (OS) rate. Cox-regression
analysis was performed to identify the prognostic value, and its cumulative impact was analyzed.
Results: The 5-year DFS rate of the patients was 71.94% and the 5-year OS rate was 81.5%. The prognostic values
for the 5-year DFS rate and 5-year OS rate were T4 stage and preoperative anemia in a multivariate analysis. Each
patient group who had no prognostic value, single, or both factors revealed 95.35%, 69.06%, and 28.57% in the
5-year DFS rate, respectively (p < 0.0001). The 5-year OS rate also showed the significant differences in each group
who had no prognostic value, single, or both factors revealed 100%, 79.3%, and 45.92%, respectively (p < 0.0001).
Conclusion: Our results showed similar efficacy to MOSAIC study in stage II and stage III colon cancer patients
treated with adjuvant FOLFOX chemotherapy after curative resection. Patients who had T4 stage and/or
preoperative anemia showed worse prognosis than patients without any prognostic value. These findings suggest
that FOLFOX could not be effective in the patients with T4 stage colon cancer accompanied by preoperative
anemia.
Keywords: Colon cancer, FOLFOX, T4 stage, AnemiaBackground
Colorectal cancer is the second most common cancer in
the USA and the third most common cancer in Korea
[1]. The most important treatment for colon cancer is
surgical resection. However, 40% to 50% of these post-
surgical patients eventually experience recurrence or die
from metastatic lesions [2,3]. In the 1990s, O’Connell
et al. [4] reported low recurrence and mortality rates in
patients with stage III colon cancer who had received* Correspondence: bkbsur@yahoo.co.kr
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unless otherwise stated.5-fluorouracil (5-FU) and low-dose leucovorin (LV) in-
jections as chemotherapy after surgical resection. The
Intergroup Trial (INT-0035) reported that administra-
tion of 5-FU and levamisole injections as adjuvant
chemotherapy after surgery in patients with stage III
colon cancer decreases the mortality rate by 33% [5].
Subsequently, many reports suggested that a 5-FU and
LV combination became the standard adjuvant treatment
for stage III colon cancer [6,7].
The MOSAIC (Multicenter International Study of
Oxaliplatin/5-FU/LV in the Adjuvant Treatment of
Colon Cancer) trial reported that the FOLFOX chemo-
therapeutic regimen, for which oxaliplatin (a third-s is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
An et al. World Journal of Surgical Oncology  (2015) 13:64 Page 2 of 8generation platinum derivative alkylating agent) was
added to 5-FU and LV, showed a superior disease-free
survival (DFS) rate than the 5-FU and LV (LV5FU2)
regimen [8,9]. Additional follow-up observations of the
MOSAIC trial continuously demonstrated that FOL-
FOX chemotherapy is advantageous in terms of both
the DFS and overall survival rates [9]. Thus, the 2013
National Comprehensive Cancer Network (NCCN)
guidelines recommend FOLFOX4 or XELOX chemo-
therapy for patients with high-risk stage II and stage III
colon cancer after surgery [10].
However, the 5-year survival rate from each stage,
American Joint Committee on Cancer (AJCC) sixth edi-
tion staging, showed paradoxically the lower survival
rate in stage IIb (72.2%) than in stage IIIa (83.4%) [3].
There should be several poor prognostic factors affecting
the survival rate even after the adjuvant chemotherapy.
FOLFOX-based adjuvant chemotherapy is a benefit for
high-risk stage II and stage III colon cancers after cura-
tive resection. But, the prognostic factor or predictive
marker for the efficacy of FOLFOX remains unclear.
This study was aimed to identify the prognostic value
and cumulative impact of adjuvant FOLFOX on the
stage II and III colon cancer patients.
Methods
Subjects
This retrospective study included 196 patients with
colon cancer who were administered FOLFOX4 chemo-
therapy after radical surgery in the Department of Sur-
gery, Busan Paik Hospital, Inje University College of
Medicine between April 2006 and December 2010. The
stage of colon cancer were classified in accordance with
the sixth edition of the AJCC TNM staging system, and
the high-risk stage II and III patients who had been
treated with adjuvant FOLFOX chemotherapy were
enrolled.
Colon cancer was defined as cancer in which the lower
tumor margin was located in the upper part of the peri-
toneum, and the stage II high-risk group must have at
least one of the following factors, including T4a/4b,
tumor perforation, bowel obstruction, poorly differenti-
ated tumor, or venous, perineural, or lymphatic invasion.
We investigated not only the postsurgical pathological
characteristics but also the ASA score and preoperative
laboratory findings, which reflected the general state of
patients before undergoing treatment, as well as the ad-
verse reactions that developed during chemotherapy.
Adverse reactions were examined by dividing them into
three categories: 1) neutropenia (cases with grade 3
or 4), 2) gastrointestinal symptoms (diarrhea, patients
prescribed loperamide, nausea or anorexia), and 3) per-
ipheral neuropathy (patients prescribed gabapentin).
Written informed consent was obtained from the patientfor the publication of this report and any accompanying
images.
Chemotherapy method and follow-up observations
LV 200 mg/m2/day was administered intravenously for
2 h. Then, a bolus IV of 5-FU 400 mg/m2 was adminis-
tered, which was followed by intravenous administration
of 5-FU 600 mg/m2 continuously for the remaining
22 h. This regimen was continued for 2 days. Oxaliplatin
85 mg/m2 was infused for 2 h only on day 1. A prophy-
lactic antiemetic and sufficient fluid were infused on
days 1 and 2 of chemotherapy. This regimen was admin-
istered every 2 weeks. The adjuvant chemotherapeutic
regimen was carried out for a total of 12 cycles.
Patients were followed up every 3 months for the first
2 years after surgery and every 6 months thereafter for
3 years, for a total of 5 years of follow-up. History, phys-
ical examination, and serum carcinoembryonic antigen
levels were determined at each follow-up visit. Chest X-
ray and abdominopelvic computed tomography scans
were performed to assess the efficacy of chemotherapy
every four cycles and every 6 months after completion of
chemotherapy. A colonoscopy was performed annually.
Recurrence was identified by imaging studies and colon-
oscopy and was confirmed by colonoscopic or percutan-
eous biopsy. Radiologically identified tumor growth
within the previous surgical field was considered to indi-
cate recurrence when histological confirmation was not
possible.
Statistical analysis
This study was the observational setting. The oncologic
outcome was analyzed with 5-year DFS and 5-year over-
all survival (OS) rate. Each survival rate was analyzed
with the Kaplan-Meier method. Cox proportional haz-
ards model was used for the univariate and multivariate
analyses of factors affecting the prognosis. The Kaplan-
Meier method and log-rank test were conducted to com-
pare the DFS and OS rates among risk groups. A p value
<0.05 was considered to indicate significance. SAS ver.




The mean follow-up period was 61 ± 31 months, and
among the 219 patients, 23 patients had been lost during
their follow-up. A total of 196 patients were included
[age range 26 to 76 years, median age 57 years, 112
males (57.1%) and 84 females (42.9%)]. In total, 147 pa-
tients (75%) were <65 years, and 49 patients (25%) were
≥65 years. A total of 174 patients (88.8%) belonged to
the category of moderately differentiated tumors and
174 patients (88.8%) belonged to the T3 stage, whereas
Table 1 Clinicopathologic characteristics of the patients
Characteristic Number %
Total patients 196










Sigmoid and rectosigmoid 119 60.7
Histologic appearance
Well differentiated 6 3.1
Moderately differentiated 174 88.8
Poorly differentiated 10 5.1
Signet ring cell 1 0.5
Mucinous cell 5 2.5
Lymphovascular invasion (+) 106 54.1











<4,000 × 106/L 3 1.5
4,000 ~ 10,000 × 106/L 169 86.2
>10,000 × 106/L 24 12.3
Hemoglobin (Hgb)
Female <12 g/dL (anemia) 50 25.5
Female ≥12 g/dL (normal) 34 17.3
Male <14 g/dL (anemia) 66 33.7
Male ≥14 g/dL (normal) 46 23.5
Platelet (PLT)
<140 × 109/L (thrombocytopenia) 4 2.0
140 ~ 440 × 109/L 185 94.4
>440 × 109/L 7 3.6
Albumin
<3.8 g/dL 40 20.4
Table 1 Clinicopathologic characteristics of the patients
(Continued)
3.8 ~ 5.3 g/dL 156 79.6
Lactate dehydrogenase (LDH)
129 ~ 240 U/L 41 20.9
>240 U/L 155 79.1
Total bilirubin
0.2 ~ 1.0 mg/dL 189 96.4
>1.0 mg/dL 7 3.6
Aspartate aminotransferase (AST)
10 ~ 33 U/L 174 88.8
>33 U/L 22 11.2
Alanine aminotransferase (ALT)
4 ~ 50 U/L 183 93.4
>50 U/L 13 6.6
Protein
<6.7 g/dL 29 14.8
6.7 ~ 8.3 g/dL 165 84.2
>8.3 g/dL 2 1.0
Prognostic model (T4, Hgb)
Low-risk group 43 21.9
Intermediate-risk group 139 70.9
High-risk group 14 7.2
Preoperative CEA
≤5 ng/mL 114 58.2
>5 ng/mL 82 41.8
Postoperative CEA
≤5 ng/mL 160 81.6
>5 ng/mL 36 18.4
Side effect
Neutropenia 154 78.6
Gastrointestinal symptoms 36 18.4
Peripheral neuropathy 40 20.4
CEA, carcinoembryonic antigen; WBC, white blood cell.
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tients, 158 patients completed a total chemotherapy of
12 cycles. Thirty-eight patients did not complete all
chemotherapy cycles due to neutropenia, gastrointestinal
symptoms (diarrhea, nausea, or anorexia), peripheral
neuropathy, or cancer recurrence. Of the 196 patients,
154 (78.6%) had neutropenia, 36 (18.4%) had gastrointes-
tinal symptoms, and 40 (20.4%) had peripheral neur-
opathy (Table 1).
Analysis of survival rates (DFS, OS) and prognostic factors
The 5-year DFS rate of the all patients was 71.94% and
the 5-year OS rate was 81.5% (Figure 1). The 5-year DFS
rates of the high-risk stages II and III were 77.78% and
Figure 1 5-year DFS and OS of total patients. DFS, disease free survival; OS, overall survival.
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high-risk stages II and III were 91.67% and 79.17%, re-
spectively (Figure 2).
In the univariate analysis, prognostic factors for DFS
were T4 stage (p = 0.0018), preoperative anemia (p =
0.0019), and preoperative thrombocytopenia (p = 0.0444),
and prognostic factors for OS were T4 stage (p = 0.005),
preoperative anemia (p = 0.0143), preoperative thrombo-
cytopenia (p = 0.0485), postoperative carcinoembryonic
antigen (CEA) (p = 0.0019), and low albumin level (p =
0.0298) (Table 2). Statistically significant factors in the
univariate analysis were included in a multivariate
analysis.Figure 2 5-year DFS and OS of stage II vs. stage III. DFS, disease free suIn the multivariate analysis, prognostic factors for DFS
were T4 stage (p = 0.0032) and preoperative anemia (p =
0.0043) (Table 3). And the prognostic factors for OS were
T4 stage (p = 0.0124), postoperative CEA (p = 0.0032), and
preoperative anemia (p = 0.0313) (Table 4).
Prognostic models were prepared using the two com-
mon prognostic factors, T4 stage and preoperative
anemia. These prognostic models were classified into
the following three groups: 1) low-risk group without ei-
ther of these prognostic factors, 2) intermediate-risk
group with only one prognostic factor, and 3) high-risk
group with both prognostic factors. Each patient group
who had no prognostic value (low-risk group), singlervival; OS, overall survival.
Table 2 Univariate analysis of prognostic factors for DFS
and OS


















Histology (differentiation ) Well
Moderately 0.5575 0.9728
Poorly 0.9001 0.894
Signet ring cell 0.1424 0.1516
Mucinous cell 0.8841 0.8773
WBC 4,000 ~ 10,000 ×
106/L
<4,000 × 106/L 0.8888 0.9328
Hgb Normal
Anemia 0.0019 0.0143
PLT 140 ~ 440 × 109/L
Thrombocytopenia 0.0444 0.0485
>440 × 109/L 0.6451 0.7521
Albumin 3.8 ~ 5.3 g/dL
<3.8 g/dL 0.3055 0.0298
LDH 129 ~ 240 U/L
>240 U/L 0.1801 0.2756
Total bilirubin 0.2 ~ 1.0 mg/dL
>1.0 mg/dL 0.2247 0.8442
AST 10 ~ 33 U/L
>33 U/L 0.1258 0.4506
ALT 4 ~ 50 U/L
>50 U/L 0.4121 0.7752
Protein 6.7 ~ 8.3 g/dL










Preoperative CEA ≤5 ng/mL
>5 ng/mL 0.4768 0.2144
Postoperative CEA ≤5 ng/mL










ALT, alanine aminotransferase; ASA, American Society of Anesthesiologists;
AST, aspartate aminotransferase; CEA, carcinoembryonic antigen; GI symptoms,
gastrointestinal symptoms (diarrhea, constipation, anorexia); Hgb, hemoglobin;
LDH, lactate dehydrogenase; PLT, platelet; WBC, white blood cell.
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group) revealed 95.35%, 69.06%, and 28.57% in the 5-
year DFS rate, respectively (p < 0.0001). The 5-year OS
rate also showed the significant differences in each
group who had no prognostic value (low-risk group),
single (intermediate-risk group), or both factors (high-
risk group) revealed 100%, 79.3%, and 45.92%, respect-
ively (p < 0.0001) (Figure 3). The multivariate analysis of
each risk group for DFS showed that the hazard ratio
(HR) of the intermediate-risk group was 7.401 (95% con-
fidence interval (CI) 1.786 to 30.67, p = 0.0058) and that
of the high-risk group was 19.296 (95% CI 4.197 to
88.723, p = 0.0001) (Table 3).
Discussion
We assessed the 5-year DFS rate, 5-year OS rate, and
prognostic factors that affected treatment of patients
with colon cancer in the high-risk stage II group and pa-
tients in stage III. These patients underwent adjuvant
FOLFOX4 chemotherapy after surgery. Numerous stud-
ies have reported that adjuvant chemotherapy after rad-
ical surgery improves the survival rate of patients with
stage III colon cancer [6-9].
In the MOSAIC trial, the 5-year DFS rate for patients
with stage III colon cancer, who underwent adjuvant
FOLFOX chemotherapy, was 73.3%. This figure was su-
perior to the 67.4% 5-year DFS rate of LV5FU5 chemo-
therapeutic regimen (HR 0.80, 95% CI 0.68 to 0.93, p =
0.003) [8,11]. However, no significant differences were
observed between the two groups in the 5-year DFS rate
or overall survival rate of patients with stage II colon
Table 3 Multivariate analysis of prognostic factors for DFS




4 2.747 1.402 5.383 0.0032
Hgb Normal
Anemia 5.505 1.708 17.745 0.0043
PLT 140 ~ 440 × 109/L
Thrombocytopenia 3.213 0.976 10.581 0.0549
>440 × 109/L 1.14 0.273 4.758 0.8574
Postoperative CEA ≤5
>5 1.672 0.91 3.073 0.0975
Prognostic model (T4-Hgb) Low risk
Intermediate risk 7.401 1.786 30.67 0.0058
High risk 19.296 4.197 88.723 0.0001
CEA, carcinoembryonic antigen; Hgb, hemoglobin; PLT, platelet.
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and Bowel Project (NSABP) C-07 trial compared the on-
cologic outcomes of FLOX (oxaliplatin + leucovorin +
fluorouracil) and FULV (leucovorin + fluorouracil), adju-
vant chemotherapeutic regimens, in patients with stage
III colon cancer. The 5-year DFS rate of the group
treated with FLOX chemotherapy was 69.4%, whereas
that of the group treated with FULV chemotherapy was
64.2% (HR 0.82, 95% CI 0.72 to 0.93, p < 0.001) [11,13].
We investigated 196 patients, belonging to the high-risk
stage II or stage III groups, who underwent adjuvant
FOLFOX4 chemotherapy after radical surgery, and
found a 5-year DFS rate of 71.94% and 5-year OS rate of
81.5%. The 5-year DFS and 5-year OS rate of the 160 pa-
tients in stage III showed 70.62% and 79.17%, separately.
This outcome was similar to that of the MOSAIC
or NSABP C-07 trials, representative investigations inTable 4 Multivariate analysis of prognostic factors for OS







PLT 140 ~ 440 × 109/L
Thrombocytopenia 2.288
>440 × 109/L 1.244
Postoperative CEA ≤5
>5 2.961
CEA, carcinoembryonic antigen; Hgb, hemoglobin; PLT, platelet.which oxaliplatin was added to the FULV chemothera-
peutic regimen.
There are numerous variables for the candidates
for the prognostic factors of FOLFOX chemotherapy.
McMillan et al. [14] reported that not only objective
cancer staging but also nutritional state and factors
reflecting systemic inflammation (weight loss, CRP in-
crease, or decreased albumin) affect the prognosis after
cancer treatment. Lee et al. [15] analyzed prognostic fac-
tors in 1,455 patients with progressive gastric cancer, who
were treated with taxotere, taxol, FOLFOX, FOLFIRI,
or FOLFOXIRI chemotherapeutic regimens. They re-
ported that decreased albumin, increased alkaline phos-
phatase, bone metastasis, or ascites adversely affected
the survival rate. But we chose the three categories affect-
ing adjuvant FOLFOX4 chemotherapy according to 1) pa-








Figure 3 5-year DFS and OS of low vs. intermediate vs. high-risk group. DFS, disease free survival; OS, overall survival.
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undergoing treatment, and 3) postsurgical pathologic fea-
tures. In this study, the multivariate analysis showed that
T4 stage and preoperative anemia were the significant
prognostic factors for both DFS and OS. Snaebjornsson
et al. [16] reported that pT4 stage, among many variables
analyzed in patients with stages II and III colon cancer, is
the most important indicator of a poor prognosis. They
also reported that it had significance equal to that of
lymph node status. In a comparison of stages pT4 and
pT3 among 352 patients with stage II colon cancer, the 5-
year survival rates were 50% and 82%, respectively (HR
2.92, 95% CI 1.67 to 5.10, p < 0.001). Gunderson et al. [17]
reported that pT4N0M0 stage II tumors have a poorer
prognosis than pT1-2 N1-2 M0 stage III tumors. Thus,
pT4 stage is a rather important independent prognostic
factor in the treatment of colon cancer. Pretreatment
anemia is associated with poor prognosis in variable can-
cers such as lung cancer, cervical cancer, head and neck
cancer, and esophageal cancer [18-21]. Qiu et al. reported
that pretreatment anemia (HR 0.084, 95% CI 0.037 to
0.191, p < 0.001) and thrombocytosis (HR 3.475, 95% CI
1.564 to 7.721, p = 0.002) in colorectal cancer patients
might be useful prognostic markers [22]. Anemia in colo-
rectal cancer patients is thought to be due to inflamma-
tory cytokines and occult bleeding, and anemia can cause
intratumoral hypoxia [23]. Intratumoral hypoxia might be
an important factor in the activation of hypoxia-inducible
factor-1, which can contribute in the acceleration of
tumor metastasis [24]. We also established a prognostic
model using T4 stage and preoperative anemia. The high-
risk group (HR 19.296, 95% CI 4.197 to 88.723, p =
0.0001) with both factors, T4 stage, and preoperativeanemia showed a significantly worse prognosis than the
other two groups.
Conclusion
In conclusion, our results showed similar efficacy to the
MOSAIC study in stage II and stage III colon cancer
patients treated with adjuvant FOLFOX chemotherapy
after curative resection. Patients who had T4 stage and/
or preoperative anemia showed worse prognosis than
patients without any prognostic value. These findings
suggest that FOLFOX could not be effective in the pa-
tients with T4 stage colon cancer accompanied by pre-
operative anemia. Therefore, much caution and aggressive
additional adjuvant treatment should be used when
treating T4 stage colon cancer patients accompanied
by preoperative anemia with FOLFOX-based adjuvant
chemotherapy.
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